Previous 10 | Next 10 |
Calliditas Therapeutics: Year-End Report, 2020 Positive Topline Results from Pivotal Phase 3 NefIgArd Trial PR Newswire STOCKHOLM , Feb. 18, 2021 /PRNewswire/ -- "On November 8, 2020 , we announced positive topline readout of Part A of our Phase 3 pivotal...
First Patient Dosed in NefIgArd Open Label Extension Study PR Newswire STOCKHOLM , Feb. 4, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the first patient has been dosed in the global open-label extension (OLE) of th...
Calliditas Therapeutics AB (CALT) has announced that the company has terminated the previously announced proposed global offering due to deterioration in market conditions."Calliditas is well capitalized with a cash runway into Q3 of 2022 and we believe there are financing options which ...
Calliditas announces termination of the proposed global offering PR Newswire STOCKHOLM , Jan. 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; Nasdaq - CALT) today announced that despite significant interest, it wil...
Calliditas Therapeutics ([[CALT]] -10.3%) launched a proposed public offering of American Depositary Shares (representing two common shares), in the U.S. for trading on Nasdaq Global Select Market and a concurrent private placement of common shares (global offering).Size of the glob...
Calliditas Therapeutics launches proposed global offering PR Newswire STOCKHOLM , Jan. 26, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX: CALTX) (Nasdaq: CALT) will today launch a proposed public offering of American Depo...
Calliditas Therapeutics ([[CALT]]) has announced that all 360 patients have been enrolled for the global Phase 3 trial NefIgArd comprising Part A and Part B, evaluating the effect of Nefecon versus placebo in patients with primary IgA nephropathy (IgAN).Calliditas read out topline data from P...
Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial PR Newswire STOCKHOLM , Jan. 21, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX: CALTX) (NASDAQ: CALT) today announced that all 360 patients have been enro...
Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day Calliditas announces clinical development plan for setanaxib and comments on data from Part A of NefIgArd study at today´s R&D Day...
Calliditas Therapeutics' ([[CALT]] +6.4%) subsidiary Genkyotex has announced positive Phase 1 data demonstrating a favorable safety and pharmacokinetic profile of high-dose setanaxib, Genkyotex's lead asset.The study in 46 healthy volunteers demonstrated that setanaxib is well tolerated ...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Ca...
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) ( STOCKHOLM : CALTX) ("Calliditas") today announced that the Pha...
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatri...